
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$2.025
−$0.025 · -1.22%
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
前日終値
$2.025
−$0.025 · -1.22%
日中の時刻はETです。市場データは遅延する場合があります。
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
日中レンジ
現在 $2.025
52週レンジ
現在 $2.025
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
59
適正価値
センチメント
52
まちまち
リスク
53
やや高いリスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
日中レンジ
現在 $2.025
52週レンジ
現在 $2.025
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 5757万 USD | 6638.2万 USD | 6518.3万 USD | 1.07億 USD | 9666.9万 USD |
| 売上原価 | 2075.2万 USD | 2055.1万 USD | 1612.9万 USD | 4076.7万 USD | 4638.6万 USD |
| 粗利益 | 3681.8万 USD | 4583.1万 USD | 4905.4万 USD | 6663.2万 USD | 5028.3万 USD |
| 研究開発 | — | 132.6万 USD | 276.9万 USD | 409.5万 USD | 1266.2万 USD |
| 販売・一般管理 | 4264.1万 USD | 3828.5万 USD | 4203.7万 USD | 7007.8万 USD | 6988万 USD |
| 営業費用 | 4513.3万 USD | 5365.8万 USD | 5064.5万 USD | 8369.7万 USD | 1.6億 USD |
| 受取利息 | — | — | — | — | 1.4万 USD |
| 支払利息 | −189.5万 USD | 370.3万 USD | 479.2万 USD | 496.3万 USD | 1.47億 USD |
| 減価償却費と償却費 | 393万 USD | 537.7万 USD | 672.5万 USD | 881.5万 USD | 1014.6万 USD |
| 営業利益 | −831.5万 USD | −782.7万 USD | −159.1万 USD | −1706.5万 USD | −1.1億 USD |
| 純利益 | −1425.2万 USD | −1356.2万 USD | −1584.4万 USD | −1705.1万 USD | −1.09億 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI38.7万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF21.1万0.00%954億 USD0.05%$235+0.80%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.28万0.00%455.91億 USD0.17%$84.44+0.44%
Dimensional - US Core Equity 2 ETFDFAC1.2万0.00%885.96億 USD0.21%$45.33+0.49%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.12万0.00%61.81億 USD0.26%$68.28+0.25%
Dimensional - US Sustainability Core 1 ETFDFSU9850.250.00%23.92億 USD0.15%$48.11+0.48%
Dimensional - US Small Cap ETFDFAS9024.10.00%338.69億 USD0.31%$78.35+0.32%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR
Dimensional - US Core Equity 2 ETFDFAC
U.S. Vector Equity Portfolio ETF Class SharesDXUV
Dimensional - US Sustainability Core 1 ETFDFSU
Dimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。